INmune Bio Inc. (INMB) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the InMuneBio first quarter 2025 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. You may withdraw yourself from the queue by pressing star 2. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce, excuse me, Mr. David Moss, CFO of ImmuneBio. David? Thank you, Jessie, and good afternoon, everyone. We thank you for joining us for the call for ImmuneBio's first quarter 2025 financial results. With me on the call today are Dr. RJ Tessie, CEO of ImmuneBio, and Dr. Mark Lodell, Chief Scientific Officer of ImmuneBio. We'll provide an update on our cords for many immune programs. Also on the call is Dr. C.J. Barnum, head of neuroscience, who will be here to answer questions. Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbors provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC. There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements which speak only as to ...